BridgeBio Pharma's Phase 3 study for BBP-418 in limb-girdle muscular dystrophy showed positive results, potentially leading to the first approved treatment for this condition.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
BridgeBio Pharma (BBIO) Is Up 13.0% After Positive Phase 3 BBP-418 Results in Muscular Dystrophy
